PCI-32765: a novel Bruton's tyrosine kinase inhibitor for the treatment of lymphoid malignancies

By Winer Eric S   Ingham Randall R   Castillo Jorge J  

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 3, 2012-03 ,pp. : 355-361

Informa Healthcare

Access to resources Recommend Favorite

Tyrosine Kinases as New Molecular Targets in Treatment of Inflammatory Disorders and Leukemia

By  

Current Pharmaceutical Design, Vol. 10, Iss. 10, 2004-04 ,pp. : 1083-1091

Bentham Science Publishers

Access to resources Recommend Favorite

Tyrosine kinase inhibitors in acute and chronic leukemias

By Ohanian Maro   Cortes Jorge   Kantarjian Hagop   Jabbour Elias  

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 7, 2012-05 ,pp. : 927-938

Informa Healthcare

Access to resources Recommend Favorite

Abelson Tyrosine-Protein Kinase 1 as Principal Target for Drug Discovery Against Leukemias. Role of the Current Computer-Aided Drug Design Methodologies

By  

Current Topics in Medicinal Chemistry, Vol. 12, Iss. 24, 2012-12 ,pp. : 2745-2762

Bentham Science Publishers

Access to resources Recommend Favorite

Therapeutic potential of tyrosine kinase 2 in autoimmunity

By Liang Yan   Zhu Yan   Xia Yi   Peng Hui   Yang Xiao-Ke   Liu Yan-Yan   Xu Wang-Dong   Pan Hai-Feng   Ye Dong-Qing  

Expert Opinion on Therapeutic Targets, Vol. 18, Iss. 5, 2014-05 ,pp. : 571-580

Informa Healthcare

Access to resources Recommend Favorite